On a corporate action affecting ordinary shares of 2seventy bio, Inc. (TSVT)

On March 10, 2025, 2seventy bio, Inc. entered into a merger agreement under which it will be acquired by Bristol Myers Squibb. 2seventy bio, Inc. stockholders will receive $5.00 in cash for each share of 2seventy bio, Inc. they own. Transaction is expected to close in the second quarter of 2025. For more details, please, refer to the company’s website.  

ITS Ltd. will publish separate notices on the procedures undertaken by ITS Ltd. to process this corporate action outlining how trading in these qualified investments will be carried out.